Signacor
1 known investors
SignaCor is a clinical-stage biotech company developing Cardiaza, a first-in-class injectable epigenetic (DNA methylation inhibiting) therapy for symptomatic hypertrophic cardiomyopathy that targets underlying disease mechanisms such as cardiac fibrosis rather than only symptoms. Spun out of Queen's University Belfast, the company focuses on therapeutics for cardiac disease.
Founders & leadership
DC
Dr Chris WatsonFounder
Investors · 1
Frequently asked questions
- What does Signacor do?
- SignaCor is a clinical-stage biotech company developing Cardiaza, a first-in-class injectable epigenetic (DNA methylation inhibiting) therapy for symptomatic hypertrophic cardiomyopathy that targets underlying disease mechanisms such as cardiac fibrosis rather than only symptoms. Spun out of Queen's University Belfast, the company focuses on therapeutics for cardiac disease.
- Who founded Signacor?
- Signacor was founded by Dr Chris Watson.
- Who are Signacor's investors?
- Signacor's investors include Clarendon Fund Managers Ltd..